Evidence map›Paper›PMID 24997440›Full record

ReviewJournal of molecular and cellular cardiology2014

An integrated mechanism of cardiomyocyte nuclear Ca(2+) signaling.

Cristián Ibarra, Jose Miguel Vicencio, Manuel Varas-Godoy, Enrique Jaimovich, Beverly A Rothermel, Per Uhlén, Joseph A Hill, Sergio Lavandero

Open access · greenAbstract readReview
In one paragraph

Review in Journal of molecular and cellular cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Inositol 1,4,5-trisphosphate receptors in cardiomyocyte physiology and disease.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022
    Review
  3. Sarcoplasmic reticulum CaPhysiological reports · 2018
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Nuclear calcium in cardiac myocytes.Journal of cardiovascular pharmacology · 2015
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 5 countries.

Cristián IbarraCardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca R&D, Mölndal, Sweden. Electronic address: cristian.ibarra@astrazeneca.com.
Jose Miguel VicencioHatter Cardiovascular Institute, University College London, London, United Kingdom.
Manuel Varas-GodoyDepartment of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Enrique JaimovichCentro de Estudios Moleculares de la Célula, Facultad de Ciencias Químicas y Farmacéuticas & Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Beverly A RothermelDepartment of Internal Medicine, Cardiology Division, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Per UhlénDepartment of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Joseph A HillDepartment of Internal Medicine, Cardiology Division, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Sergio LavanderoCentro de Estudios Moleculares de la Célula, Facultad de Ciencias Químicas y Farmacéuticas & Facultad de Medicina, Universidad de Chile, Santiago, Chile; Department of Internal Medicine, Cardiology Division, University of Texas Southwestern Medical Center, Dallas, TX, USA; Advanced Center for Chronic Diseases, Facultad de Ciencias Químicas y Farmacéuticas & Facultad de Medicina, Universidad de Chile, Santiago, Chile. Electronic address: slavander@uchile.cl.
Karolinska Institutet · SEThe University of Texas Southwestern Medical Center · USAdvanced Center for Chronic Diseases · CLAstraZeneca (Netherlands) · NLUniversity College London · GBUniversity of Chile · CL

Funding

Microenvironmental control of progenitors in organ dysfunction and repairU01HL100401 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI OLSON, ERIC N, SCHNEIDER, JAY W · 2009 to 2015
$8.3M
Modulating Calcineurin Signaling Pathways in MuscleR01HL072016 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI ROTHERMEL, BEVERLY A · 2003 to 2012
$3.7M
Calcineurin's role in circadian regulation of cardiac function and remodelingR01HL097768 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI ROTHERMEL, BEVERLY A · 2009 to 2012
$1.6M
STIM1: Master Regulator of Calcium Homeostasis in CardiomyocytesR01HL120732 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI HILL, JOSEPH A · 2013 to 2016
$1.6M
NHLBI NIH HHS HL-072016NHLBI NIH HHS HL-097768NHLBI NIH HHS HL100401NHLBI NIH HHS HL-120732NHLBI NIH HHS R01 HL072016NHLBI NIH HHS R01 HL097768NHLBI NIH HHS R01 HL120732NHLBI NIH HHS U01 HL100401
6 · The paper itself

Abstract

In cardiomyocytes, Ca(2+) plays a central role in governing both contraction and signaling events that regulate gene expression. Current evidence indicates that discrimination between these two critical functions is achieved by segregating Ca(2+) within subcellular microdomains: transcription is regulated by Ca(2+) release within nuclear microdomains, and excitation-contraction coupling is regulated by cytosolic Ca(2+). Accordingly, a variety of agonists that control cardiomyocyte gene expression, such as endothelin-1, angiotensin-II or insulin-like growth factor-1, share the feature of triggering nuclear Ca(2+) signals. However, signaling pathways coupling surface receptor activation to nuclear Ca(2+) release, and the phenotypic responses to such signals, differ between agonists. According to earlier hypotheses, the selective control of nuclear Ca(2+) signals by activation of plasma membrane receptors relies on the strategic localization of inositol trisphosphate receptors at the nuclear envelope. There, they mediate Ca(2+) release from perinuclear Ca(2+) stores upon binding of inositol trisphosphate generated in the cytosol, which diffuses into the nucleus. More recently, identification of such receptors at nuclear membranes or perinuclear sarcolemmal invaginations has uncovered novel mechanisms whereby agonists control nuclear Ca(2+) release. In this review, we discuss mechanisms for the selective control of nuclear Ca(2+) signals with special focus on emerging models of agonist receptor activation.

Indexed as

Calcium SignalingAnimalsCalcium ChannelsCell NucleusCytosolHumansModels, BiologicalMyocytes, CardiacCalcium ChannelsAngiotensin IICardiomyocyteEndothelin-1Insulin-like growth factor-1Nuclear Ca(2+)Sarcolemmal receptor

Identifiers

PMID24997440
PMCPMC4626248
OpenAlexW2114698330

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.